Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is frequently in the news as a global provider of innovative and comprehensive laboratory services. Company announcements highlight activities across diagnostics, oncology, neurology, consumer testing and biopharma laboratory services, giving investors and healthcare professionals insight into how Labcorp is evolving its business and scientific capabilities.
Recent press releases have covered topics such as quarterly financial results, updated full-year guidance and cash dividends on Labcorp’s common stock. These items show how the company communicates its financial performance, capital allocation decisions and participation in investor conferences and healthcare industry events.
Labcorp’s news flow also emphasizes developments in specialty testing. The company has reported on the expansion of its Plasma Detect molecular residual disease portfolio for monitoring recurrence risk in certain breast, lung and colon cancers, and on clinical studies featuring its MRD technology in journals such as Nature Medicine and Clinical Cancer Research. In neurology, Labcorp has announced plans to offer the Elecsys pTau181 blood test, cleared by the U.S. Food and Drug Administration to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline.
Other news items describe collaborations and transactions, including agreements to acquire select outreach laboratory assets from health systems, the sale of select early development medical device testing assets to NAMSA, and partnerships that expand access to at-home testing through Labcorp OnDemand. Governance updates, such as board appointments and executive retirements, are also disclosed through company news.
This page aggregates these types of updates, allowing readers to follow Labcorp’s announcements on clinical testing innovations, oncology and neurology offerings, consumer-focused services, strategic partnerships, financial results and corporate governance.
Labcorp (NYSE: LH) and PathAI have expanded their strategic partnership focusing on AI-powered pathology. This collaboration will enable seamless deployment of PathAI algorithms in clinical trials managed by Labcorp. Key objectives include enhancing patient stratification and developing companion diagnostic devices using robust AI-driven analytics. Labcorp aims to leverage this collaboration to advance drug development and improve patient outcomes, reflecting significant developments in digital pathology.
Walgreens has partnered with Labcorp to sell the Pixel by Labcorp COVID-19 PCR Test Home Collection Kits over-the-counter at 6,000 stores nationwide. Starting spring 2021, this will be Walgreens' first in-store testing option, enhancing access in underserved areas. Walgreens aims to increase its on-site testing capacity to over 5,000 locations by April 1. The kits allow customers to self-administer tests and send samples to Labcorp for processing. Test results will be available online, with follow-up by healthcare professionals for positive results.
Labcorp (NYSE: LH) announced that its executive management team will participate in a virtual fireside chat at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on February 25 at 1:30 p.m. ET. A live webcast of the event will be available on the company's website and archived for later replay.
As a leading global life sciences company, Labcorp reported $14 billion in revenue for FY2020 and employs over 75,000 people serving clients in more than 100 countries, providing vital insights and innovations to improve health.
Labcorp (NYSE: LH) has launched a new laboratory-based antigen test to help determine active COVID-19 infections. Developed by DiaSorin, this test requires a doctor's order and is conducted using a nasal or nasopharyngeal swab. Results are typically available within 24-48 hours. Labcorp emphasizes that while PCR tests remain the gold standard for COVID-19 diagnosis, antigen tests are an important tool for assessing infection status. The test has been made available in the U.S. following FDA notification on October 26, 2020.
Labcorp (NYSE: LH) announced that its CMO, Amy Summy, was named on the 2021 Forbes CMO Next list for her leadership during the COVID-19 pandemic. Her contributions include spearheading a successful rebranding strategy and launching the Pixel by Labcorp™ at-home testing kits. Recognized for innovation and impact in healthcare, Summy emphasized the role of Labcorp employees in fighting COVID-19. The company reported a revenue of $14 billion in FY2020 and aims to improve patient outcomes across various diseases.
Labcorp (NYSE: LH) reported a strong performance for Q4 and full year 2020, with revenues of $4.49 billion in Q4, a 52% increase year-over-year, driven by COVID-19 testing and a growing base diagnostics business. Net earnings rose to $938.3 million, or $9.54 per diluted share. For 2021, the company projects revenue growth of 1% to 4% and expects a 50% decline in COVID-19 testing revenues. Labcorp emphasized its commitment to science and innovation and anticipates free cash flow between $1.70 billion and $1.90 billion.
Labcorp (NYSE: LH) has announced the appointments of Dr. Prasanth Reddy as senior vice president and enterprise oncology head, and Dr. Robert Phillips as vice president and head of enterprise oncology science. This move aims to strengthen Labcorp's capabilities in cancer diagnosis, treatment, and drug development. Dr. Reddy and Dr. Phillips bring extensive experience in oncology and drug-linked diagnostics from their previous positions at Foundation Medicine and Daiichi-Sankyo, respectively. Labcorp continues to expand its leadership in advancing innovative cancer solutions.
Labcorp (NYSE: LH) has appointed Dr. Deborah Ann Sesok-Pizzini as its new Chief Medical Officer of Labcorp Diagnostics, effective January 11, 2021, following Dr. Dot Adcock's retirement in April 2021. Dr. Sesok-Pizzini brings over 20 years of healthcare experience, having previously served in various leadership roles at The Children's Hospital of Philadelphia and as a professor at the University of Pennsylvania. Dr. Brian Caveney expressed enthusiasm about her contributions to the team.
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
